Global Chronic Kidney Disease (CKD) Drugs Market to 2029 – Featuring AbbVie, Allergan and Amgen Among Others –

Global Chronic Kidney Disease (CKD) Drugs Market to 2029 – Featuring AbbVie, Allergan and Amgen Among Others –

Global Chronic Kidney Disease (CKD) Drugs Market to 2029 – Featuring AbbVie, Allergan and Amgen Among Others –

DUBLIN–(BUSINESS WIRE)–The “Chronic Kidney Disease (CKD) Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2019 to 2029” report has been added to’s offering.

This report provides detailed insights into key market determinants that impacted the market across geographies and drug types.

The report also includes market estimation and forecast for CKD drugs for geographic region for 2019 -2029. The forecast period was 2021 to 2029, historic period included 2019 and base year 2020. The drug class considered in the report was antihypertensive, antihyperlipidemic, anemia treatment drugs, swelling treatment drugs and other medications. The report provides in-depth analysis on each market segment across drug classes and geographies and estimates that would enable the decision makers to make pre informed decisions.

Chronic kidney disease (CKD) is also known as chronic kidney failure or renal disease is a condition characterized by a gradual loss of kidney function over time. Key market determinant include rising geriatric populace, increment in prevalence of CKD and favorable insurance policies in developed economies.

Chronic kidney disease is a non-communicable disease (NCD). About 850 million people across the world are diagnosed with CKD and is estimated to become the fifth most reason of death in the world by 2040. Key factors driving the CKD drugs market include increasing prevalence of diabetes, cardiovascular disease and CKD and increasing geriatric population.

More than 10% of the adults were diagnosed by CKD as per Centers for Disease Control and Prevention (CDC). Increasing prevalence of diabetes and hypertension increased the risk of CKD. About 1 in 3 adults were diagnosed for diabetes and 1 in 5 adults with hypertension. Antihypertensive medication contributed to the largest market in the year 2019. ACE inhibitors and diuretics remain as the first line treatment for CKD. Erythropoietin stimulating agents is also used significantly to deal with anemia which is the common complication among CKD affected patients.

For the purpose of this study, the global chronic kidney disease (CKD) drugs market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa(MEA)

North America was the market leader in terms of market revenues for CKD drugs market in 2019 in which the U.S. had the highest contribution of market revenues. The key factors that influenced the U.S. CKD market is the increasing obesity rate, increasing prevalence of diabetic patient. The pipeline molecule such as ABT-614 (Abbott laboratories), EOS789 (Chugai Pharmaceutical) has significant potential. Increasing funding from government agencies and healthcare organizations had a significant role in driving the market for CKD drugs.

As per Centers for Disease Control and Prevention, more than 20 million people are diagnosed with CKD every year in the U.S. Europe remained the second largest market in terms of revenues for CKD drugs. High prevalence rate of CKD was the key driver in Europe. However, the highest growth rate was highest in Asia Pacific during the forecast period on 2021 to 2029. The key drivers in Asia Pacific includes rising incidence of diabetes and cardiovascular disorders, emerging healthcare set up and regulations, increased population, increasing development, per capita income and healthcare spending, increasing government initiatives and increase in awareness level among the public.

Key Topics Covered:

Chapter 1 Preface

Chapter 2 Executive Summary

Chapter 3 Chronic Kidney Disease (CKD) Drugs Market Analysis

3.1 Global Chronic Kidney Disease (CKD) Drugs Market Overview

3.2 Market Dynamics

3.2.1 Market Drivers High prevalence of Chronic Kidney Disease (CKD)

3.2.2 Challenges

3.2.3 Opportunities

3.3 Attractive Investment Proposition

3.4 Competitive Landscape of Key Players in Chronic Kidney Disease (CKD) Drugs Market

Chapter 4 Global Chronic Kidney Disease (CKD) Drugs Market, by Drug Class

4.1 Overview

4.2 Antihypertensive

4.3 Antihyperlipidemic

4.4 Anemia Treatment Drugs

4.5 Swelling Treatment Drugs

4.6 Other

Chapter 5 Global Chronic Kidney Disease (CKD) Drugs Market, By Geography

5.1 Preface

5.2 North America (U.S. & Canada)

5.3 Europe (U.K., Germany & Rest of Europe)

5.4 Asia Pacific (China, Japan and Rest of APAC)

5.5 Latin America

5.6 Middle East and Africa

Chapter 6 Company Profiles

6.1 AbbVie, Inc.

6.2 Allergan plc.

6.3 Amgen Inc.

6.4 AstraZeneca plc.

6.5 F. Hoffmann-La Roche Ltd

6.6 FibroGen

6.7 GlaxoSmithKline plc.

6.8 Johnson & Johnson

6.9 Keryx Biopharmaceuticals, Inc.

6.10 Kissei Pharmaceutical Co., Ltd

6.11 Pfizer, Inc.

6.12 Sanofi S.A.

6.13 Teva Pharmaceutical Industries Ltd.

For more information about this report visit


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900